ArticleScientific reports2019

Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.

Chun-Hsien Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.